Board shake-up: Syndax loses director as Incyte names Meury chief executive

Rhea-AI Filing Summary

Syndax Pharmaceuticals (Nasdaq:SNDX) filed an 8-K under Item 5.02 reporting the resignation of director William Meury, effective June 24 2025. Meury stepped down to become President, CEO and board member of Incyte Corporation, Syndax’s collaboration partner on Niktimvo™ (axatilimab-csfr). The company states the departure involves no disagreements regarding its operations, policies or practices. No successor or board-composition changes were disclosed.

While day-to-day operations and partnership terms remain unchanged, investors should watch for follow-up filings detailing any replacement director or shifts in oversight of the Incyte collaboration.

Positive

• None.

Negative

• Resignation of director William Meury, who served as a direct link to collaboration partner Incyte, introduces potential oversight gap for the Niktimvo program.

Insights

Corporate Governance Expert

TL;DR: Governance intact; liaison to key partner exits.

The resignation removes the board’s most direct conduit to Incyte, yet it is amicable and unlinked to policy disputes. Board size and independence metrics are unchanged, so immediate governance risk is limited. However, replacing Meury with a director equally versed in the Niktimvo collaboration will be important for strategic continuity and information flow. Absent a timely appointment, oversight of this late-stage asset could weaken, potentially elongating decision cycles or diluting negotiating leverage in joint steering committees. Watch upcoming proxy or 8-K filings for a replacement and any committee realignments.

Biotech Collaboration Analyst

TL;DR: Partnership optics shift; operational terms unchanged.

Incyte elevating Meury to CEO strengthens the partner’s commitment to Niktimvo, but his exit from Syndax’s board removes cross-company visibility. Because collaboration economics and development timelines are untouched, near-term financial forecasts stand. Still, governance asymmetry may tilt future co-commercialization negotiations toward Incyte. Investors should monitor whether Syndax secures a replacement with comparable commercial expertise or deeper immunology credentials to preserve balance.

0001395937false00013959372025-06-242025-06-24

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 24, 2025

SYNDAX PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-37708	32-0162505
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
730 THIRD AVENUE FLOOR 9
NEW YORK, New York				10017
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (781) 419-1400

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		SNDX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 24, 2025, William Meury notified Syndax Pharmaceuticals, Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”) due to his acceptance of the role of President and Chief Executive Officer and a member of the Board of Directors at Incyte Corporation, the Company’s collaboration partner for Niktimvo™ (axatilimab-csfr). Mr. Meury’s resignation from the Board is effective June 24, 2025, and is not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			SYNDAX PHARMACEUTICALS, INC.
Date:	June 26, 2025	By:	/s/ Michael A. Metzger
			Michael A. Metzger Chief Executive Officer

FAQ

Why did SNDX director William Meury resign?

He accepted the roles of President, CEO and board member of Incyte Corporation, effective June 24 2025.

When is William Meury's resignation from SNDX effective?

The resignation became effective on June 24 2025.

Did Meury leave due to any disagreement with Syndax?

No. The 8-K states his departure is not due to any disagreement on operations, policies or practices.

How could Meury’s departure affect the Niktimvo collaboration?

It removes a direct board-level liaison to Incyte, potentially impacting strategic oversight, though collaboration terms remain unchanged.

What SEC item covers this disclosure for SNDX?

The resignation is reported under Item 5.02 – Departure of Directors or Certain Officers of Form 8-K.